Coherus Oncology, Inc. (CHRS) Profit Margins
Over the twelve months to 2026-06-30, Coherus Oncology, Inc. (CHRS) had gross margin 68.9%, operating margin -311.6%, net margin -259.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CHRSCoherus Oncology, Inc.Follow CHRS — free
—
Price chart with a free account
- Market cap
- 156.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | 92.1% | 82.4% | 66.8% | 38.2% | 66.9% | 67.2% | 68.9% | |
| Operating margin | -207.9% | -729.2% | -61.0% | -14918.8% | 30.3% | 32.9% | -80.8% | -121.7% | -79.0% | -756.6% | -429.5% | -311.6% | |
| Net margin | -280.1% | -743.2% | -67.0% | -15306.6% | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 108.0% | 398.4% | -259.4% | |
| FCF margin | -86.1% | -380.0% | -136.3% | -13165.7% | 7.5% | 30.9% | -11.9% | -115.2% | -68.1% | — | — | — |
USD millions · SEC XBRL
Coherus Oncology, Inc. — questions
- What is Coherus Oncology, Inc.'s gross margin?
- 68.9% over the twelve months to 2026-06-30.
- What is Coherus Oncology, Inc.'s operating margin?
- -311.6% over the twelve months to 2026-06-30.
- What is Coherus Oncology, Inc.'s net profit margin?
- -259.4% over the twelve months to 2026-06-30.
Every figure on this page comes from Coherus Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.